ReviewEuropean journal of clinical pharmacology2026
Innovative applications of artificial intelligence technology in pharmacometrics.
Review in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pharmacometrics, as the core discipline of model-informed drug development paradigm, quantitatively characterizes drug exposure-response dynamics using mathematical models. However, its traditional methodology, represented by nonlinear mixed-effects modeling, is inherently resource-intensive and often struggles to fully capture complex biological variability. The rapid advancement of artificial intelligence technologies offers a transformative data-driven paradigm, providing superior efficiency and predictive accuracy. Yet, the artificial intelligence approaches suffer from the “black box” constraint. This review detailed the deep, complementary integration of artificial intelligence and pharmacometrics, demonstrating how this synergy is necessary to satisfy the complex, triple demands of accuracy, efficiency, and regulatory explainability. We systematically explored innovative applications across the entire pharmacometrics workflow, including model optimization, covariate screening, virtual population generation, etc. In each section, we also presented specific application cases or workflows. Furthermore, we outlined current challenges in the implementation of artificial intelligence and proposed a vision for interdisciplinary and cross-institutional collaboration.
Indexed as
Identifiers
41872613What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.